TL;DR: Zolgensma, a groundbreaking gene therapy for spinal muscular atrophy, has sparked debate over its $2 million price tag, reflecting the complex interplay between essential drug development supported by public funds and the for-profit motives of biotech companies. The narrative reveals a troubling trend in the pharmaceutical industry where patient needs are often overshadowed by profit-driven pricing strategies. https://www.propublica.org/article/zolgensma-sma-novartis-drug-prices-gene-therapy-avexis #law #tech #legaltech ⚖️ 🤖 #autosum